BNTX CHMP opinion: Thursday, September 17, 2026
Variation type II · COMIRNATY · A grouped application consisting of: Type II (C.12): Submission of final report from study C4591052 listed as a category 3 study in the RMP. This is a non-interventional Post-Authorization Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicro
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.